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OBJECTIVES We sought to determine whether income-based disparities in care processes and outcome
exist in patients with acute coronary syndromes.
BACKGROUND Using income proxies and limited clinical data, some observational studies have shown
income disparities in outcome after acute myocardial infarction (MI).
METHODS Using annual household income from the economic substudy of the PURSUIT (Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy)
trial, patients were grouped into low-, middle-, and high-income categories based on the U.S.
Census Bureau definition of poverty. Logistic regression analysis was used to examine the
association between income category and the use of cardiac procedures and the prescription
of evidence-based medications at hospital discharge. Cox regression analysis was used to
examine the hazard of 30-day and six-month death or recurrent MI across income categories,
after adjusting for baseline characteristics.
RESULTS Low-income patients had more chronic medical conditions and were sicker at presentation.
Among low-income patients, the use of some evidence-based medications and cardiac
procedures was lower and the unadjusted rates of 30-day death and six-month death or MI
was higher. After multivariable adjustment, there was no consistent pattern for disparity in
care processes, but the trend for higher short and intermediate-term death or MI persisted for
low-income patients.
CONCLUSIONS Income level is associated with a trend toward worse outcome among patients with acute
coronary syndromes. The disparity in 30-day and six-month death or MI between low and
high-income patients could not be readily explained by differences in in-hospital medical or
invasive treatment, suggesting that the poor outcomes may be due to differences occurring
after hospital discharge. (J Am Coll Cardiol 2003;41:1948–54) © 2003 by the American
College of Cardiology Foundation
Although the number of Americans living in poverty has
decreased over the past decade, the U.S. Census Bureau
reports that 11% of the population still falls below the
poverty level (1). Epidemiologic studies suggest that poverty
is associated with a higher incidence of ischemic heart
disease (2,3) and a higher mortality after acute myocardial
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infarction (MI) (4–6). Proposed explanations for the rela-
tionship between income level and coronary disease include
higher burden of cardiac risk factors, such as poor diet and
cigarette smoking, and/or reduced access to medical care
(5,7–11).
Previous studies of the relationship between income level
and coronary artery disease have generally used proxies for
income such as level of education (12–14), gross national
product (GNP) (15), or median income of the zip code of
residence (5,9) rather than directly measuring household
income. In addition, many studies used population registries
(4,16) or administrative data (5,9) that may have had limited
clinical data.
The economic substudy of the Platelet Glycoprotein
IIb/IIIa in Unstable Angina: Receptor Suppression Using
Integrilin Therapy (PURSUIT) trial (17) contains self-
reported income from a large subset of patients enrolled in
the U.S. and presents an ideal setting in which to investigate
the influence of income level on process of care and
outcome. The purpose of this analysis was threefold: first, to
determine the association between household income and
the medical and invasive treatment of acute ischemic heart
disease; second, to determine the association between
household income and both the short and intermediate-
term occurrence of death or recurrent MI; and third, to
explore the relationship among income, processes of care,
and outcomes.
METHODS
Patient population. The study population consisted of
patients enrolled in the economic and quality of life
(EQOL) substudy of the PURSUIT trial. Details of the
trial methods have been published previously (18). Briefly,
the PURSUIT trial (n  10,498) randomized patients with
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unstable angina or non–Q-wave MI to either eptifibatide or
placebo. Patients were eligible if they had ischemic chest
pain within the prior 24 h, and transient electrocardio-
graphic changes or elevated markers of myocardial necrosis.
Concomitant medical therapy, including aspirin, and car-
diac procedures were left to the discretion of the treating
physician. The EQOL substudy of patients randomized in
the U.S. (n  3,522) was prospectively conducted concur-
rent with the main PURSUIT investigation (17). A random
sample consisting of 70% of patients enrolled in the U.S. (n
 2,464) were enrolled. Patients in the substudy were asked
to complete a questionnaire that contained self-reported
annual household income in addition to other questions
regarding activities of daily living and functional status.
Patients checked one of six boxes on the questionnaire that
corresponded to their annual household income: $10,000;
$10,001 to $20,000; $20,001 to $30,000; $30,001 to
$45,000; $45,001 to $60,000; and $60,000.
Definitions and end points. The U.S. Census Bureau
defines poverty based on a set of income thresholds that vary
by family size. Only pretax income is considered, and
families or individuals with income below the corresponding
poverty threshold are considered to be poor. For the
purposes of this study, we defined three income categories
based on self-reported annual household income: $20,000
(low-income), $20,000 to $60,000 (middle-income), and
$60,000 (high-income). A cutoff of $20,000 was used to
define the lowest income group because this corresponds
approximately to twice the “Weighted Average Poverty
Threshold” used by the Census Bureau in 1995 to define
poverty for householders aged 65 or older.
The main outcome measures were the occurrence of
death or MI at 30 days and six months. The occurrence of
MI at 30 days was defined as new chest pain and ST-
segment elevation within 18 h of enrollment, new or repeat
creatine kinase-MB fraction (CK-MB) elevation above
upper limit of normal after 18 h, or CK-MB elevation above
three times the upper limit of normal after percutaneous
coronary intervention (PCI) and above five times the upper
limit of normal after coronary artery bypass graft (CABG)
surgery (18). All suspected infarctions and deaths occurring
between enrollment and 30 days were evaluated by a masked
clinical events committee. Events occurring between 30 days
and six months were assessed from hospital discharge
summaries and death certificates.
Statistical analysis. We compared baseline patient charac-
teristics across the three income categories using chi-square
tests for categorical variables and the nonparametric
Kruskal-Wallis tests for continuous variables. A value of p
 0.05 was considered significant. Univariate and multiva-
riable logistic regression analyses were used to examine the
association between income category and the use of cardiac
procedures within 30 days of enrollment and prescription of
evidence-based medications at discharge from the index
hospitalization. Specifically, models were developed to
examine the independent association between income
and the use of cardiac catheterization, PCI, CABG, as
well as prescription of aspirin, beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors, and lipid-lowering
medications, after adjusting for key baseline variables such
as age, gender, race, hypertension, diabetes, congestive heart
failure, peripheral vascular disease, and MI at enrollment.
Odds ratios and 95% confidence intervals were generated
for the low-income group using the high-income group as
the reference and were converted to relative risks using the
method of Zhang and Yu (19).
Kaplan-Meier analysis was used to examine six-month
survival free of recurrent MI across income categories.
Survival curves were compared using the log-rank test
statistic. Cox regression analysis was used to calculate
baseline-adjusted hazard of 30-day and six-month death or
recurrent MI across income categories. A comprehensive set
of variables found to be significantly associated with 30-day
death/recurrent MI in a previously published model based
on the entire PURSUIT cohort (20) were included in a
backward stepwise model. These included age, gender,
weight, height, diabetes, smoking status, worst Canadian
Cardiovascular Society class in the last six weeks, peripheral
vascular disease, prior beta-blocker use, prior calcium chan-
nel blocker use, prior use of nitrates, systolic blood pressure,
diastolic blood pressure, rales, presence of ST-segment
depression0.5 mm, time to treatment, and treatment with
eptifibatide. Income category was forced into the models to
examine the relative hazard of death or recurrent MI among
low-income patients compared to high-income patients.
Ethics of protocol. The Institutional Review Boards of all
participating institutions reviewed and approved the proto-
cols of the PURSUIT trial. All patients enrolled gave
written informed consent for the collection of financial and
resource-use data.
RESULTS
Baseline characteristics. Of the 2,464 patients in the U.S.
EQOL substudy of the PURSUIT trial, 2,207 (90%) had
completed self-reported income data and six-month follow-
up, and they constitute the current study’s patient popula-
tion. No significant differences existed in baseline charac-
teristics of patients included in the study and in the overall
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass graft surgery
CK-MB  creatine kinase-MB fraction
EQOL  economic and quality of life
GNP  gross national product
MI  myocardial infarction
PCI  percutaneous coronary intervention
PURSUIT  Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using
Integrilin Therapy trial
SES  socioeconomic status
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U.S. cohort. Based on our definition of income categories,
1,000 (45%) of the study patients were classified as low-
income; 952 (43%) as middle-income; and 255 (12%) as
high-income. Table 1 shows the baseline clinical character-
istics of the patients across the three income groups.
Patients in the low-income category were older and more
likely to be women, black, and living alone. There was also
a higher prevalence of risk factors for heart disease such as
hypertension, diabetes, prior CABG, and prior congestive
heart failure among low-income patients. Upon presenta-
tion, they were more likely to have ST-segment depression
and evidence of pulmonary edema, and they had slightly
longer time from symptom onset to randomization (p 
0.09).
Care processes. As shown in Table 2, the rates of
evidence-based medical therapy prescribed at hospital dis-
charge varied among the income groups. There was lower
use of aspirin and beta-blockers in the low-income patients
compared with the middle-income patients. Compared with
both the middle- and high-income patients, low-income
patients had a lower rate of lipid-lowering drugs prescribed
at discharge (27.0% for low-income; 32.2% for middle-
income; 36.1% for high-income, p  0.01) but higher rates
of ACE inhibitors (32.9% for low-income; 24.1% for
middle-income; 22.4% for high-income, p  0.01). With
regard to procedures, significantly fewer low-income pa-
tients underwent cardiac catheterization and PCI, but no
differences were seen among the income groups with respect
to CABG (Table 2). The analysis was repeated using an
income cutoff of $10,000 to define low-income, and it
produced similar results.
To account for the effect of older age among the poor, a
separate analysis stratified by age was performed. Among
patients younger than age 65, a trend was seen toward a
lower rate of evidence-based medical therapy (e.g., beta-
blockers and lipid-lowering agents) in the low-income
group (Table 3). Significantly more low-income patients
received ACE inhibitors. Significantly fewer low-income
patients underwent cardiac catheterization or PCI. No
difference existed in the rate of CABG across the income
groups. In the patients older than 65 years, significantly
fewer low-income patients received aspirin (81.3% for
low-income; 87.5% for middle-income; 93.0% for high-
income, p  0.05), beta-blockers (56.5% for low-income;
64.0% for middle-income; 68.4% for high-income, p 
0.05), and lipid-lowering agents (23.8% for low-income;
30.4% for middle-income; 36.8% for high-income, p 
0.05). More middle-income patients underwent cardiac
catheterization and PCI, but again there was no difference
in the rate of CABG across the income groups.
Outcomes. The unadjusted rate of death or MI at 30 days
was higher in the low-income group, although this was not
statistically significant (Table 2). When the components of
the composite end point were examined separately, signifi-
Table 1. Baseline Characteristics (Data Shown Are in Percentages Unless Otherwise Noted)
Low-Income
(n  1,000)
Middle-Income
(n  952)
High-Income
(n  255)
Demographics
Age, median (IQR)* 65 (55, 73) 61 (52, 69) 56 (49, 63)
Female* 45.1 25.9 18.0
Black* 20.2 7.9 2.7
Years of education* 10.5 12.7 14.9
Married* 48.4 79.5 89.0
Professional occupation* 23.6 50.3 73.7
Insurance coverage*
Private 25.9 57.4 78.3
Medicare 55.6 35.5 17.2
Medicaid 9.0 1.3 0.8
None 8.3 3.6 1.6
Other 1.1 2.2 2.0
Medical history
Diabetes* 31.1 22.3 16.9
Hypertension* 66.8 58.3 52.5
Prior PCI 22.4 21.3 18.8
Prior CABG* 22.9 19.2 14.9
Prior CHF* 15.0 7.2 2.4
Smoker* 32.9 31.5 27.2
Presenting characteristics
ST-segment depression 0.5 mm* 40.1 37.2 32.5
Rales 1/3 lung field* 2.0 1.2 1.2
Systolic blood pressure, median (IQR)* 130 (115, 146) 127 (113, 142) 124 (110, 140)
Heart rate, median (IQR)* 72 (64, 82) 70 (62, 80) 70 (62, 82)
Hours from symptom onset to
randomization, median (IQR)
12.5 (6.8, 20.5) 11.9 (5.9, 19.5) 11.3 (5.9, 19.6)
*p  0.01.
CABG  coronary artery bypass graft surgery; CHF  congestive heart failure; IQR  interquartile range; PCI 
percutaneous coronary intervention.
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cantly higher 30-day mortality was seen among the low-
income patients (3.5% for low-income; 1.9% for middle-
income; 0.4% for high-income group, p  0.01). At
six-months, the unadjusted rates of both the composite end
point and death alone were significantly higher in the
low-income group (5.6% for low-income; 3.3% for middle-
income; 1.6% for high-income, p 0.01) (Table 4). Similar
results were seen when an income cutoff of $10,000 was
used to define low-income category.
The rates of the composite six-month end point as well as
its individual components were higher than the 30-day end
point. Figure 1 shows the Kaplan-Meier rates of MI-free
survival at six months for the three income groups. The
curves separated within 30 days and continued to separate
up to six months of follow-up.
Again, an analysis stratified by age showed a trend toward
higher 30-day death or MI and six-month death or MI in
the low-income groups regardless of age (Table 3).
Multivariable modeling. Table 4 shows the adjusted rel-
ative risks of aspirin, beta-blocker, ACE inhibitor, and
lipid-lowering agent prescription at discharge, as well as
procedures by 30 days for the low-income group. After
Table 2. Unadjusted Rates of Discharge Medical Therapy, 30-
Day Cardiac Procedures, and 30-Day and 6-Month Outcomes
(Data Shown Are Percentages)
Low-
Income
(n  1,000)
Middle-
Income
(n  952)
High-
Income
(n  255)
Medical therapy
Aspirin* 83.4 87.1 85.9
Beta-blocker* 57.2 62 63.1
Lipid-lowering agent*†‡ 27.0 32.2 36.1
ACE inhibitor*†‡ 32.9 24.1 22.4
Procedures by 30 days
Cardiac catheterization*†‡ 79.3 87.6 87.8
PCI*†‡ 31.2 42.4 42.4
CABG 20.2 22.1 17.3
30-day outcomes
Death or MI 14.2 12.9 9.0
Death‡ 3.5 1.9 0.4
MI 12.3 12.0 8.6
6-month outcomes
Death or MI‡ 18.8 15.7 11.4
Death‡ 5.6 3.3 1.6
MI 15.8 14.0 9.8
*p 0.05 for comparison between the middle- and low-income groups; †p 0.05 for
comparison between the high- and low-income groups; ‡p  0.01 across the three
income groups.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft
surgery; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Table 3. Unadjusted Rates of Medical Therapy, Procedures, and Outcomes Stratified by Age (Data Shown Are Percentages Unless
Otherwise Indicated)
Income Category
Age <65 Years Age 65 Years
Low-
Income
(n  471)
Middle-
Income
(n  577)
High-
Income
(n  198)
p Value
(Across
Groups)
Low-
Income
(n  529)
Middle-
Income
(n  375)
High-
Income
(n  57)
p Value
(Across
Groups)
Medical therapy
Aspirin 85.8 86.8 83.8 0.57 81.3 87.5 93.0  0.05
Beta-blocker 58.0 60.7 61.6 0.57 56.5 64.0 68.4  0.05
Lipid-lowering agent 30.6 33.4 35.9 0.37 23.8 30.4 36.8  0.05
ACE inhibitor 30.1 21.8 22.2  0.05 35.3 27.5 22.8  0.05
Procedures by 30 days
Cardiac catheterization 82.2 89.9 91.4  0.01 76.7 84.0 75.4  0.05
PCI 34.6 46.4 45.5  0.01 28.2 36.3 31.6  0.05
CABG 17.0 19.9 15.2 0.24 23.1 25.3 24.6 0.73
30-day outcomes
Death or MI 10.4 10.2 7.1 0.37 17.6 17.1 15.8 0.94
Death 2.1 1.4 0.5 0.28 4.7 2.7 0.0 0.09
MI 9.3 9.4 6.6 0.45 14.9 16.0 15.8 0.91
6-month outcomes
Death or MI 15.0 12.7 8.6 0.08 22.2 20.3 21.4 0.79
Death 3.4 2.1 0.5 0.06 7.6 5.1 5.4 0.30
MI 13.5 11.3 8.1 0.13 17.8 18.1 16.1 0.93
Abbreviations as defined in Table 2.
Table 4. Adjusted Hazard Ratios of Discharge Medical Therapy
and 30-Day Cardiac Procedures, and Adjusted Hazard Ratios of
30-Day and 6-Month Death or Recurrent MI for Low-Income
Patients Relative to High-Income Patients
Variable
Adjusted Risk
(95% Confidence Interval)
Medical therapy*
Aspirin 1.1 (0.7–1.6)
Beta-blocker 0.9 (0.7–1.3)
Lipid-lowering agent 0.7 (0.5–1.0)
ACE inhibitor 1.2 (0.8–1.5)
Procedures by 30 days*
Cardiac catheterization 0.8 (0.6–1.3)
PCI 0.8 (0.6–1.1)
CABG 1.3 (0.9–1.8)
Outcomes†
30-day death or MI 1.3 (0.8–2.1)
6-month death or MI 1.4 (0.9–2.1)
*Relative risks adjusted for age, gender, diabetes, hypertension, congestive heart
failure, peripheral vascular disease, and myocardial infarction on enrollment. †Hazard
ratios adjusted for age, weight, height, smoking status, systolic blood pressure, heart
rate, rales, and time to treatment.
Abbreviations as defined in Table 2.
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adjustment for baseline characteristics, there did not appear
to be any pattern of disparity in care processes for the
low-income patients relative to the high-income patients.
However, the trend toward a higher risk of death or
recurrent MI at 30 days and six months persisted for the
low-income group after adjustment. Using an income cutoff
of $10,000 to define low-income produced identical
results.
DISCUSSION
The results of this study indicate that poverty is associated
with a trend toward worse short- and intermediate-term
outcomes among patients with non–ST-segment elevation
acute coronary syndromes. As income level decreased, the
risk of 30-day and six-month death or MI increased.
Interestingly, this occurred despite the apparent lack of
differences in either revascularization or medical therapy at
the time of hospital discharge. The rates of some evidence-
based medical therapies (like lipid-lowering agents) were
generally lower among the poor, but the use of other
therapies (such as ACE inhibitors) was higher. Lower
income level was associated with lower use of cardiac
catheterization and PCI, but higher rates of CABG. None
of these associations were statistically significant after con-
trolling for baseline risk factors. Although no longer statis-
tically significant, the trend toward a worse outcome per-
sisted among the poor after adjustment for baseline
differences among the income groups. Furthermore, the
six-month outcomes appeared to be worse than the 30-day
outcomes for low-income compared with high-income pa-
tients.
Our study is one of few that have examined the issue of
income in the setting of a clinical trial. Shibata and
colleagues (15) examined country-specific mortality rates
from five international randomized clinical trials of acute
ST-elevation MI. Using a country’s GNP as a proxy for
income, they found an inverse linear relationship between
GNP and mortality from MI. Evidence for differences in
care processes in a clinical trial comes from a study by
Cohen et al. (21), who examined the rates of coronary
angiography, coronary angioplasty, and bypass surgery in
Latin America among patients enrolled in the PURSUIT
trial. They found that patients enrolled in Latin America
were less likely to receive cardiac procedures and had higher
mortality than did patients enrolled outside of Latin Amer-
ica. The lack of disparity in medical and invasive therapy
among the U.S. patients enrolled in the PURSUIT trial
suggests that, in the U.S., process of care may be more
equitable for patients involved in clinical trials.
Other observational studies have found lower rates of
both evidence-based medical therapy (9) and cardiac pro-
cedures (5) among the poor. Rathore et al. (9) found that
elderly patients residing in areas in the U.S. where the
median income was less than the lowest 15th percentile of
U.S. incomes were less likely to receive reperfusion therapy,
aspirin at admission and during hospitalization, and beta-
blockers at hospital discharge even when they were consid-
ered to be “ideal” candidates for these therapies. Among
patients older than 65 years, we found a similar pattern of
lower aspirin, beta-blocker, ACE inhibitor, and lipid-
lowering agent use in low-income patients.
Using administrative data from Canada and geographic
Figure 1. Kaplan-Meier curves of myocardial infarction-free survival at six months for the three income groups. The p values are: p  0.01 by the log-rank
test for comparison between the high-income and low-income groups; p  0.08 by the log-rank test for comparison between the middle-income and
low-income groups; p  0.10 for comparison between the high-income and middle-income groups.
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proxies for income, Alter et al. (5) found a direct relation-
ship between socioeconomic status (SES) and access to
coronary angiography and revascularization procedures, and
an inverse relationship between SES and mortality from
acute MI. In our age-stratified analysis, significantly fewer
low-income patients younger than age 65 underwent cardiac
catheterization and PCI. Among patients older than age 65,
however, we were unable to find any consistent pattern of
disparity in revascularization procedures by income level.
This pattern of lower use of evidence-based medical therapy
but similar rates of procedures may be due to federal
coverage of procedures for patients 65 years and older in the
U.S. through the Medicare entitlement.
The aforementioned observational studies provide valu-
able information on the association between income level
and process of care, but they have two major limitations.
First, administrative databases may have limited clinical
information. Our study was performed using data from a
clinical trial where data collection is rigorous. Second, these
observational studies all used proxies for income such as
median income of the neighborhood of residence, GNP of
the country of origin, or education level. These measures
provide important, but indirect, data on personal income,
and may suffer from the “ecologic fallacy” of misclassifying
income level on the basis of geographic economic factors,
which can lead to substantial measurement error (22,23). To
avoid this pitfall, we used patients’ self-reported income and
found that lower household income level was associated
with generally higher short- and intermediate-term death or
recurrent MI.
This was present despite the lack of association between
low income and lower use of procedures in the inpatient
setting or medical therapy at discharge. Other potential
mechanisms by which poverty is associated with adverse
outcomes include differences in patient or community char-
acteristics. Patient-level differences can occur at multiple
levels, from health status to medication compliance and
insurance coverage. The poor had higher rates of hyperten-
sion, diabetes, and prior congestive heart failure, which can
reflect either lack of medical care prior to admission or the
effect of poverty itself. For example, low SES has been
associated with lower rates of exercise and higher rates of
smoking, and higher lipid levels and higher blood pressure
(24).
In addition, the poor are intuitively less able to afford
prescription drugs, which can lead to suboptimal compli-
ance with discharge medications. Although many types of
healthcare insurance (including Medicaid in many states)
provide medication coverage, a greater proportion of pa-
tients in the low-income group were Medicare beneficiaries.
The Medicare program does not currently provide medica-
tion coverage, and it is unknown whether the provision of a
drug benefit would increase compliance and improve out-
comes among the elderly poor. Community-level differences
may also explain the widened gap between 30-day and
six-month mortality (25). Neighborhoods may differ in
access to medical care facilities, the number of advertise-
ments for tobacco products (26), and safety. All these
factors, alone or in concert, may explain the association
between low income and adverse events after hospital
discharge.
Study limitations. There are some limitations to our study.
First, patients who were poor were older than were patients
in the other income groups, and it is possible that the
disparities in outcome were driven to a large extent by age.
However, after age stratification and adjustment for clinical
characteristics, the mortality differences persisted in low-
income patients older than age 65. Second, we did not
examine the effect of income level on compliance with
discharge medications, which may be responsible for the
increased death and recurrent MI among low-income pa-
tients seen at six months. Further research is needed to
determine the differences among income groups in the
outpatient setting, including differences in compliance, so-
cial support, and access to primary care. Third, our study did
not have the statistical power to examine the effect of
different insurance coverage on care processes or outcome.
Fourth, the lack of racial heterogeneity in our sample
precluded our ability to examine an interaction between
income and race. Finally, our study cohort was comprised of
participants in a clinical trial; therefore, our results may not
be applicable to the general population of patients with
acute coronary syndromes.
Conclusions. In conclusion, our study indicates that pov-
erty, measured as household income, is associated with a
generally worse outcome in patients with non–ST-segment
elevation acute coronary syndromes. The trend toward a
higher risk of short- and intermediate-term death or recur-
rent MI among low-income patients was present despite the
lack of income-related differences in inpatient care processes
such as cardiac procedures and prescription of evidence-
based medicines at hospital discharge. A number of post-
discharge factors, rather than in-hospital care, may be
responsible. More study is needed to determine whether
disparities in follow-up care after hospital discharge, med-
ication compliance, social support, or a combination of these
factors account for the worse outcomes among the poor.
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